Why Aging Raises Cancer Metastasis Risk
Cancer is the leading cause of death in people over 65. Moreover, metastasis — the spread of cancer to distant organs — drives most of these deaths. Scientists have long known that aging increases cancer risk. However, the precise biological mechanisms linking aging to aggressive metastasis have remained poorly understood.
A landmark study published in Nature Aging now offers critical new answers. Researchers demonstrate that tiny particles released by aging liver cells actively promote cancer spread across multiple tumor types. Furthermore, they identify specific molecular targets that could form the basis of new anti-metastatic treatments. This discovery reshapes how scientists understand the relationship between cellular aging and cancer progression.
What Are Extracellular Vesicles
Tiny Particles With Major Impact
Extracellular vesicles (EVs) are small, membrane-enclosed particles that cells release into the bloodstream. They carry proteins, lipids, and genetic material — including microRNAs — to distant sites throughout the body. Consequently, EVs act as biological messengers, influencing the behavior of cells far from their origin.
Why the Source Matters
Not all EVs behave the same way. EVs from healthy young cells tend to support normal tissue function. In contrast, EVs from aged or stressed cells can carry damaging cargo. The new study focuses specifically on EVs released by senescent hepatocytes — liver cells that have entered a state of permanent cell cycle arrest associated with aging.
How the Aging Liver Triggers Pan-Cancer Spread
The study, conducted in mouse models, shows that EVs from senescent hepatocytes promote metastasis across multiple different tumor types. This pan-cancer effect is a particularly striking finding. It suggests that the aging liver does not simply decline in function. Instead, it actively creates a systemic environment that makes tumors across the body more invasive.
Aged liver tissue shows measurable changes. Specifically, it accumulates senescent cells and undergoes metabolic shifts that alter EV production. These changes allow the liver to flood the bloodstream with pro-metastatic signals. Tumor cells throughout the body then absorb these signals, gaining new invasive capabilities as a result.
The Role of P2RX7 in Vesicle Release
A Key Molecular Gateway
Researchers identify elevated expression of a receptor called P2X purinoceptor 7, or P2RX7, in aged liver tissue. This receptor plays a central role in EV biogenesis — the process by which cells generate and release extracellular vesicles. Therefore, higher P2RX7 activity in aging liver cells directly drives the increased production of pro-metastatic EVs.
A Druggable Target
Importantly, P2RX7 is already known to scientists, and inhibitors of this receptor exist. The study shows that blocking P2RX7 significantly reduces metastasis in aged mice. This finding opens an immediately actionable therapeutic avenue. Researchers suggest that repurposing existing P2RX7 inhibitors could help control age-associated metastatic spread in cancer patients.
miRNAs: The Hidden Messengers Driving Metastasis
Four Key microRNAs Identified
Inside the age-derived EVs, researchers identify four specific microRNAs: miR-25, miR-92a, miR-30c, and miR-30d. These small RNA molecules travel through the bloodstream inside EVs and reach primary tumor sites. Once there, they alter gene expression in tumor cells, boosting their invasiveness and metastatic potential.
How They Silence Tumor Suppressors
These four miRNAs work by suppressing two key tumor suppressor genes — PTEN and LATS2. PTEN normally restrains cell growth and invasion. LATS2 functions as part of the Hippo signaling pathway, which controls tissue growth and organ size. When miR-25, miR-92a, miR-30c, and miR-30d silence PTEN and LATS2, they remove critical brakes on tumor cell behavior. As a result, tumor cells undergo epithelial-mesenchymal transition (EMT) — a process that makes cancer cells more mobile and capable of invading new tissues.
What Clinical Evidence Reveals
The findings extend beyond mouse models. Clinical samples from older cancer patients confirm the same molecular patterns observed in aged mice. Specifically, tumor tissues from older patients show reduced PTEN and LATS2 expression alongside enhanced EMT markers. Additionally, the four pro-metastatic miRNAs appear at elevated levels in the tumor tissues of older patients compared to younger counterparts.
This clinical validation is crucial. It demonstrates that the aging liver-EV-miRNA axis is not merely a laboratory phenomenon. Rather, it reflects a real biological process occurring in aging human cancer patients, making the research directly relevant to clinical oncology.
Promising Therapeutic Strategies
Senolytics: Clearing Senescent Cells
One approach the study tests is targeting senescence directly. Researchers use dasatinib and quercetin (D+Q), a well-known senolytic drug combination that selectively clears senescent cells from the body. Treatment with D+Q substantially reduces metastasis in aged mice. This suggests that eliminating senescent hepatocytes may cut off the supply of pro-metastatic EVs at its source.
Silencing Harmful miRNAs
A second strategy targets the miRNAs themselves. By silencing miR-25, miR-92a, miR-30c, and miR-30d, researchers considerably reduce tumor spread in aged mice. This approach offers a more targeted intervention. Rather than broadly clearing senescent cells, it blocks specific molecular signals that drive metastasis.
Inhibiting P2RX7
As noted earlier, blocking P2RX7 suppresses EV biogenesis in aged liver cells, thereby reducing the volume of harmful vesicles entering the bloodstream. Together, these three strategies — senolytics, miRNA silencing, and P2RX7 inhibition — provide a multi-pronged framework for future therapies aimed at reducing age-related cancer metastasis.
